Epigral Limited — Important, 27-01-2025: Financial Result Updates

**Consolidated Financials:**

**Revenue:** Epigral Limited reported a total revenue of ₹649.10 crore for the quarter ended December 31, 2024, reflecting a strong growth of 37% year-over-year compared to ₹473.98 crore in the same quarter of the previous year. This growth is attributed to increased demand and expanded market presence within the domestic market.

**Profit & EPS:** The company achieved a net profit of ₹103.63 crore, up significantly from ₹49.08 crore in the same quarter last year. This translates to an Earnings Per Share (EPS) of ₹24.25, compared to ₹11.81 for the prior period. The increase in profitability can be primarily attributed to improved operational efficiencies despite rising costs.

**Operational Costs:** Total expenses for the quarter were ₹495.57 crore, an increase from ₹399.82 crore a year ago, marking a rise of 24%. Key contributors to this surge included higher costs of materials consumed and employee benefits. Operational cost management initiatives remain critical as the company navigates these increases.

**Balance Sheet & Cash Flow:** Total equity stands at ₹1,212.55 crore, demonstrating solid financial health. The recent Qualified Institutional Placement has strengthened the balance sheet, enabling strategic investments and debt repayment, which will potentially enhance liquidity and reduce financial risk.

**Strategic Position and Outlook:** The results indicate a robust strategic focus on maintaining cost efficiency while capitalizing on market growth opportunities within the Chloro Alkali sector. The company remains optimistic about future growth driven by its market strategies and operational improvements.

**Investor Insight:** Given the strong revenue growth and notable profitability improvements, the outlook is positive. A buy stance may be justified for investors seeking exposure to robust growth in the sector, while close monitoring of operational costs is advised.